Recent Company News

• 02:16 PM ET May 13, 2026
  

  FDA approves sNDA for INQOVI combo for AML in adults 75+ years of age (¥11145.0000, 0)

• 10:47 AM ET May 07, 2026
  

  CORRECTION: MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema (HAE) in patients 12 years and older ($75.76, -1.10)

• 05:35 PM ET Apr 28, 2026
  

  Otsuka Holdings upgraded to buy from neutral at UBS (¥11180.0000, 0)

• 07:07 AM ET Apr 28, 2026
  

  Cullinan Therapeutics announces FDA accepts NDA for zipalertinib for treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations ($13.25, 0.00)

• 12:33 AM ET Apr 28, 2026
  

  Otsuka Holdings reports Q1 net income attributable ¥98.35B vs FactSet ¥76.08B [5 est, ¥70.93-88B] (¥11275.0000, +630)

• 01:50 PM ET Apr 24, 2026
  

  Stifel comments on the latest CNPV vouchers; identifies winners and remains upbeat on others

• 08:53 AM ET Apr 24, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:25 AM ET Apr 24, 2026
  

  EMA CHMP publishes summary of opinions for April 2026 meeting

• 06:21 AM ET Apr 24, 2026
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Inaqovi (¥10810.0000, 0)

• 09:29 AM ET Apr 20, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 18-Apr